The Kv1.3 channel, a classical Shaker-type potassium channel, holds a unique place in cellular biology. Unibest presents two Kv1.3 inhibitor assets, UB024 and UB029, for NewCo and License opportunities.
In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104.
The transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo.
New Approval of Olaparib IndicationOn January 2nd, AstraZeneca and Merck jointly announced that their PARP inhibitor Lynparza® (Generic name: olaparib) has received approval for a new indication in China.
The topic of this report is a long-acting HIV "vaccine" called Lenacapavir, developed by Gilead Sciences in the United States.
We, Unibest, are excited to share with you the remarkable benefits and opportunities that Reteplase brings to the global market.